Seres Therapeutics, Inc. (MCRB) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2019)
MCRB's revenue distribution by segment and geography for fiscal year 2019
By Product/Segment
MCRB Revenue Analysis (2013–2024)
As of March 5, 2026, Seres Therapeutics, Inc. (MCRB) generated trailing twelve-month (TTM) revenue of $351,000. The most recent quarter (Q3 2025) recorded $351,000 in revenue.
Looking at the longer-term picture, MCRB's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $144.9 million in 2021.
Revenue diversification analysis shows MCRB's business is primarily driven by License And Service (100%). With over half of revenue concentrated in License And Service, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ARMP (-7.6% YoY), EVGN (-26.2% YoY), and SYBX (-100.0% YoY). Compare MCRB vs ARMP →
Peer Comparison
Compare MCRB's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| MCRBCurrent | $351,000 | - | - | - | |
 ARMP | $5M | -7.6% | - | -820.2% | |
 EVGN | $9M | -26.2% | +62.4% | -255.4% | |
 SYBX | $8,000 | -100.0% | -67.6% | -511875.0% | |
 ELAB | $2M | -179.8% | - | -75.7% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $0 | - | $-3,532,000 | - | $-121,315,000 | - |
| 2023 | $0 | - | $0 | - | $-195,097,000 | - |
| 2022 | $0 | -100.0% | $0 | - | $-179,914,000 | - |
| 2021 | $144.9M | +336.3% | $144.9M | 100.0% | $-64,493,000 | -44.5% |
| 2020 | $33.2M | -3.7% | $-57,355,000 | -172.7% | $-88,130,000 | -265.3% |
| 2019 | $34.5M | +22.1% | $34.5M | 100.0% | $-71,876,000 | -208.3% |
| 2018 | $28.3M | -11.9% | $-67,688,000 | -239.5% | $-100,284,000 | -354.8% |
| 2017 | $32.1M | +47.5% | $-57,355,000 | -178.7% | $-91,395,000 | -284.7% |
| 2016 | $21.8M | - | $-60,223,000 | -276.7% | $-92,839,000 | -426.5% |
| 2015 | $0 | - | $-728,000 | - | $-54,856,000 | - |
See MCRB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MCRB Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare MCRB vs LLY
See how MCRB stacks up against sector leader Eli Lilly and Company.
Start ComparisonFrequently Asked Questions
Is MCRB's revenue growth accelerating or slowing?
MCRB TTM revenue: $351000.00. YoY growth: N/A. 5-year CAGR: N/A.
What is MCRB's long-term revenue growth rate?
Seres Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is MCRB's revenue distributed by segment?
MCRB reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.